Gracell Biotechnologies Reports the US FDA Clearance of IND Application for GC012F to Treat Multiple Myeloma
Shots:
- Following the IND clearance, Gracell expects to initiate a P-I clinical trial evaluating GC012F as an early-line treatment for patients with multiple myeloma across the US
- Additionally, GC012F is also being evaluated in a P-Ib/II clinical trial for the treatment of r/r multiple myeloma & in an expected (initiation in 2024) P-I/II trial for the treatment of rSLE. GC012F is also being evaluated in 4 investigator-initiated trials for rSLE
- According to the data presented at the ASH Annual Meeting 2023, GC012F depicted an ORR of 100% & minimum residual disease negative stringent CRR of 95.5%. GC012F is an autologous CAR-T therapy that targets BCMA & CD19 & leverages Gracell’s proprietary FasTCAR next-day manufacturing platform
Ref: Gracell Biotechnologies | Image: Gracell Biotechnologies
Related News:- AstraZeneca to Acquire Gracell Biotechnologies for ~$1.2B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
